Seminar: China's Biotech potential: what are the prospects?
Thursday 3 November 2011, 17 Hannover Square London W1S 1HU
Hosted by: Fasken Martineau
Organised by: Asia-Pacific Technology Network
* Douglas B. Andrews, CEO,Stravencon
* D Bruce Murdoch, Commercial Director, Stravencon
o "China's biopharma potential"
* Dr Jeffe Schuman MD Stravencon Corporate Services
o "the funding of biotech ventures"
* Dr Allan Syms, Sector Specialist China, Life Science Sector Team,
UK Trade & Investment
o "British interests"
* an overview of the development of biosimilars
* official Chinese speaker on Chinese policy?
China is the world's third largest pharmaceutical market and is poised to become the lead destination for international biopharma outsourcing. For the moment, the Chinese "biosimilars" industry is relatively weak, but the development capabilities of these companies is growing exponentially, at least in part due to the return of highly trained nationals. This seminar will look at China's potential in biosimilars and the wider biotechology sphere. It will raise questions about how these emerging companies can fund themselves to reach the requisite size and quality. It will then look at prospects for British companies.
Location: Fasken Martineau, 17 Hanover Square London W1S 1HU
Nearest tube station: Oxford Circus
Timing: Registration from 17:00: seminar from 17:30 - 19.15 (followed by refreshments)
* Free to Fasken Martineau clients and APTN's annual supporters
* £45 + VAT (Executives)
* £25 + VAT (Asian citizens/institutions, officials, executives from Small Companies)
* £12.50 + VAT (Academics & UKTI invitees)
* Free for the Media
To Register your interest- please send your details (name, institutional affiliation, email address, phone number - and the category you come
under) to [email protected]
Bruce has over 35 years of experience in the fields of General Management, Marketing and Corporate M&A within the global life sciencemand pharmaceutical industry. Since 1975 he has held a number of SeniormManagement positions with Rhone-Poulenc (1975-1980), AstraZenecam(1980-1990), Pharmacia (1990-1996) and Schering-Plough (1996-2002) within UK and Asian markets including Japan. He was also involved in the early entry of the pharmaceutical industry into China with a number of joint-ventures in 1988-1990. From 2002 he was Senior Vice-President of Bioaccelerate Inc in London and CEO of a small biotechnology start-up company called Genaderm Ltd. In 2006 Bruce joined Avesthagen Pvt Ltd, a Systems Biotechnology company based in Bangalore, India as Chief Business Officer. They are currently developing a number of “Biosimilars” for the world markets. In 2009 he returned to London, UK to join travencon Limited, a UK based pharmaceutical company that specialises in product trading and advisory work between EU and China. He graduated from Nottingham University in 1971 with an Honours Degree in Biological Sciences with Statistics. He has been Chairman of various Pharmaceutical branches of IFPMA and PhRMA. He is currently a member of the Institute of Directors and the China British Business Council in UK.